Lifestyle Change Implementation Research Network at PRC at UMass Chan
ConditionGLP - 1
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Massachusetts, Worcester
About this trial
The goal of this project is to study how well the Noom digital lifestyle program works for adults who are taking Glucagon-Like Peptide-1 receptor agonist (GLP-1) medications. The study team will assess how the program affects people's behaviors and health outcomes. The team will also look at how digital lifestyle change interventions can be implemented in real-world settings, including how many people it reaches, how well it is put into practice, whether people stick with it over time, and whether it works well for different groups of people.
Eligibility criteria
Qualifiers
Began using a GLP-1 within the past 6 months
Currently using GLP-1
Plans to continue GLP-1 use
GLP-1 prescribed by their physician (e.g., not online or 3rd party vendor)
Disqualifiers
Was taking a GLP-1 within the 2 months prior to the current GLP-1 start date
Currently participating in a structured lifestyle change program (receiving structured guidance and counseling on physical activity, diet or weight loss)
Currently pregnant
Trial design
Treatments tested in this trial
- Digital Lifestyle Coaching Program
Treatment groups
220 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Massachusetts, Worcester
Lead sponsor
University of Massachusetts, Lowell
Collaborator
Centers for Disease Control and Prevention
Collaborator
Source ClinicalTrials.gov